Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. | ...

After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Layoffs in biopharma show no signs of slowing, with workforce reductions holding steady across the first two quarters of 2025. | Biopharma layoffs have held steady through mid-2025, and in this ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

BD has picked a new executive to lead its planned connected care segment, as the company nears the conclusion of its ...

Researchers at Johns Hopkins University have shown that an artificial intelligence-powered robot—trained on videos of ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...